TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16450155

Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide (HCT)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 100 mg hydrochlorothiazide (HCT)
Number of subjects: 103
Study: 15016019

Group type: EXPERIMENTAL
Intervention: SRP plus tetracycline (TE) fibres
Number of subjects: 19

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 19
Study: 10368203

Group type: EXPERIMENTAL
Intervention: Intracavernosal PGE1 (20 microg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: MUSE (1 mg)
Number of subjects: 60
Study: 8874308

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (0.2 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (0.02 mg/kg)
Number of subjects: 30
Study: 1503326

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparinoid (ORG 10172), 750 anti-factor Xa units twice daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Unfractionated heparin, 5000 units subcutaneously twice daily
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparinoid (ORG 10172)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study: 6484216

Group type: EXPERIMENTAL
Intervention: CL115,574 (750 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CL115,574
Number of subjects: 8
Study: 30424980

Group type: EXPERIMENTAL
Intervention: mHELP protocols (early mobilization, oral and nutritional assistance, and orienting communication) administered daily with usual care by a trained nurse until hospital discharge
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: mHELP protocols
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control group (usual care only)
Number of subjects: 377
Study: 30658375

Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride varnish (Acclean Fluoride Varnish)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 3% oxalic acid/potassium salt solution (Super Seal Desensitizer)
Number of subjects: 22
Study: 27600167

Group type: EXPERIMENTAL
Intervention: Residential Immersive Life Skills (RILS) program (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Deferred RILS control group (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-residential life skills program (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group matched on age, diagnoses, and cognitive capacity not receiving any life skills intervention (Group D)
Number of subjects: 30
Study: 24239799

Group type: EXPERIMENTAL
Intervention: Predictive model for any medical complications
Number of subjects: 1476

Group type: EXPERIMENTAL
Intervention: Predictive model for major medical complications
Number of subjects: 1476
Study: 23775972

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem-cell transplantation (HSCT)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Number of subjects: 208
Study: 20345274

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galdakao-modified supine Valdivia position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 0
Study: 18196225

Group type: EXPERIMENTAL
Intervention: Fingolimod (5 mg single dose) + Atenolol (50 mg once daily for 5 days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fingolimod (5 mg single dose) + Diltiazem (240 mg once daily for 5 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Fingolimod alone
Number of subjects: 25
Study: 15736778

Group type: EXPERIMENTAL
Intervention: Bovine porous bone mineral (BPBM), guided tissue regeneration (GTR), and platelet-rich plasma (PRP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Open-flap debridement
Number of subjects: 28
Study: 12953276

Group type: EXPERIMENTAL
Intervention: Bilateral transplantation with one donor per side
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Bilateral transplantation with four donors per side
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 34

Group type: COMPARATOR
Intervention: Four-donor group vs. placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Stratification based on disease severity
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Transplanted patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Striatal fluorodopa uptake
Number of subjects: 34
Study: 10962136

Group type: EXPERIMENTAL
Intervention: Vitamin E 200 mg/day for 10 days/month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8664131

Group type: COMPARATOR
Intervention: 3 weekly regimen of cisplatin 60 mg m‐2 i.v. on day 1 and etoposide 120 mg m‐2 i.v. on day 1 and 100 mg b.d. orally on days 2 and 3 alternating with cyclophosphamide 600 mg m‐2 i.v., doxorubicin 50 mg m‐2 i.v. and vincristine 2 mg i.v. all on day 1 for a maximum of six courses (3 weekly)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: 10/11 day regimen with the same drugs but with each course consisting of half the 3 weekly dose given every 10 or 11 days for a maximum of 12 courses
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Quality of life measured using a daily diary card (DDC)
Number of subjects: 167
Study: 1839902

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (mean dose 25 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Metoprolol (mean dose 200 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Chlorthalidone/Metoprolol combination (logroton)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 33
Study: 6340079

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 40
Study: 31964369

Group type: EXPERIMENTAL
Intervention: Fascination 2 ceramic brackets
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pearl ceramic brackets
Number of subjects: 60
Study: 31403221

Group type: EXPERIMENTAL
Intervention: Senior managers' awareness of sun safety policies
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Increased communication about sun safety to employees
Number of subjects: 68
Study: 28914355

Group type: EXPERIMENTAL
Intervention: Jet CPAP device
Number of subjects: 170

Group type: COMPARATOR
Intervention: Bubble CPAP device
Number of subjects: 170
Study: 27899094

Group type: EXPERIMENTAL
Intervention: Personalised website experience combining shared stories, education, personal goal setting, and links to resources.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online feedback and semi-structured interviews during follow-up.
Number of subjects: 0
Study: 24418244

Group type: EXPERIMENTAL
Intervention: L-arginine (6 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (6 g cornstarch)
Number of subjects: 15
Study: 22157229

Group type: EXPERIMENTAL
Intervention: CD‐5As
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: CM‐Lite
Number of subjects: 110

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 110
Study: 20923557

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (10% w/v) dental coating
Number of subjects: 983

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 983
Study: 18398664

Group type: EXPERIMENTAL
Intervention: Computerized educational session and 1 pack of EC
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group education about periconception folate supplementation
Number of subjects: 446
Study: 16000612

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with two cycles of carboplatin and paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Induction chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy
Number of subjects: 0
Study: 12800728

Group type: EXPERIMENTAL
Intervention: Lactose-containing milk (240 mL daily for 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lactose-hydrolyzed milk (240 mL daily for 14 days)
Number of subjects: 30
Study: 10483329

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (200 mg three times daily)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study: 8354803

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy with either streptokinase or recombinant tissue-type plasminogen activator within 7 hours of symptom onset (mean 4.8 hours)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy
Number of subjects: 132
Study: 3523590

Group type: EXPERIMENTAL
Intervention: First screen mammography
Number of subjects: 23101
Study: 28563974

Group type: EXPERIMENTAL
Intervention: Medtrum A6 TouchCare® CGM System
Number of subjects: 63
Study: 26613636

Group type: EXPERIMENTAL
Intervention: Strength-based case management intervention (CMI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Referral only
Number of subjects: 75
Study: 26122891

Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions at the start of CBT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions at the start of IPT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Once-weekly sessions at the start of CBT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Once-weekly sessions at the start of IPT
Number of subjects: 200
Study: 22798280

Group type: EXPERIMENTAL
Intervention: Written Asthma Action Plan (WAAP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Verbal counseling
Number of subjects: 80
Study: 22088518

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 - 120 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 19245384

Group type: EXPERIMENTAL
Intervention: Nurse case-managed approach (NCMIT)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Standard programmes with tracking (SIT)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Standard programmes without tracking (SI)
Number of subjects: 865
Study: 17003569

Group type: EXPERIMENTAL
Intervention: cilazapril for 8 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: valsartan for 8 weeks
Number of subjects: 24
Study: 15259448

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibition (abciximab) in addition to dalteparin (subcutaneous)
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: Dalteparin (subcutaneous)
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: Combination of NT-proBNP and creatinine clearance
Number of subjects: 7800

Group type: EXPERIMENTAL
Intervention: Any detectable elevation of TnT and reduced creatinine clearance
Number of subjects: 7800

Group type: COMPARATOR
Intervention: Aspirin and heparin (or dalteparin)
Number of subjects: 7800
Study: 11145323

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 9824526

Group type: EXPERIMENTAL
Intervention: Ambulatory utilization review (UR)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No ambulatory utilization review (Control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ambulatory utilization review (UR) after 4 weeks without participation
Number of subjects: 41
Study: 8062320

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide nasal aerosol (110, 220, or 440 micrograms)
Number of subjects: 93
Study: 2738596

Group type: EXPERIMENTAL
Intervention: Social work intervention (regular visits by a research social worker over 4 months)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combined results from both groups
Number of subjects: 44
Study: 31909725

Group type: EXPERIMENTAL
Intervention: iCBT‐I (internet-delivered cognitive behavioral therapy for insomnia)
Number of subjects: 177
Study: 30975977

Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI) preceded by pindolol (5-HT1AR antagonist)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 28540436

Group type: EXPERIMENTAL
Intervention: Oral melatonin (0.5 mg/kg, max 20 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg, max 20 mg)
Number of subjects: 80
Study: 26529076

Group type: EXPERIMENTAL
Intervention: 23vPPV vaccine administered during pregnancy (at 30-36 weeks gestation)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 23vPPV vaccine administered at birth
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (unvaccinated)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: 23vPPV vaccine during pregnancy (post-hoc analysis)
Number of subjects: 227
Study: 23174369

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 42
Study: 21540874

Group type: EXPERIMENTAL
Intervention: Mushroom group (28,000 IU vitamin D2 via experimental soup)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Supplement group (28,000 IU vitamin D2 via supplement)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 26
Study: 18498956

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 14566300

Group type: EXPERIMENTAL
Intervention: Coil occlusion of patent ductus arteriosus (PDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Echocardiographic variables
Number of subjects: 0
Study: 10735923

Group type: EXPERIMENTAL
Intervention: LAO (lansoprazole 30 mg o.d., amoxycillin 1 g b.d., ornidazole 500 mg b.d.)
Number of subjects: 80

Group type: COMPARATOR
Intervention: LAC (lansoprazole 30 mg o.d., amoxycillin 1 g b.d., clarithromycin 500 mg b.d.)
Number of subjects: 80
Study: 8786194

Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone
Number of subjects: 5

Group type: COMPARATOR
Intervention: Testosterone propionate
Number of subjects: 5
Study: 8471406

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2869849

Group type: EXPERIMENTAL
Intervention: Nifedipine (20, 40, and 60 mg b.i.d.)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydralazine (25, 50, and 100 mg b.i.d.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 19
Study: 31981364

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group (no MTX treatment)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Methotrexate exposure (ever use)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Dose-response association
Number of subjects: 395
Study: 30315150

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) add-on therapy (2700 mg/day) for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 26921057

Group type: EXPERIMENTAL
Intervention: Aripiprazole adjunctive treatment (5 mg/day for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-adjunctive treatment (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 60
Study: 23417688

Group type: EXPERIMENTAL
Intervention: Reduced-fat products (RF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal-fat products (NF)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: n-3-enriched reduced-fat products (n-3 RF)
Number of subjects: 22
Study: 21974983

Group type: EXPERIMENTAL
Intervention: rTMS followed by task-oriented training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham rTMS followed by task-oriented training
Number of subjects: 24
Study: 20560730

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: Valsartan 80 mg once daily
Number of subjects: 31
Study: 18627322

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day for 12 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ezetimibe plus atorvastatin
Number of subjects: 60
Study: 17518401

Group type: EXPERIMENTAL
Intervention: Robotic surgery using the Acrobot hands-on robotic system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 28
Study: 11832257

Group type: EXPERIMENTAL
Intervention: Idoxifene 5 mg per day
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Idoxifene 10 mg per day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 10234895

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study: 7862181

Group type: EXPERIMENTAL
Intervention: Extended treatment with rifampin plus isoniazid for 12 months
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo for the second 6 months
Number of subjects: 335

Group type: COMPARATOR
Intervention: No further treatment after 6 months for HIV-seronegative patients
Number of subjects: 335
Study: 1789059

Group type: EXPERIMENTAL
Intervention: 50 micrograms octreotide sc
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 2.5 mg bromocriptine po
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of both drugs
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo sc
Number of subjects: 51
Study: 7193614

Group type: EXPERIMENTAL
Intervention: Clomipramine (Anafranil) 10 mg daily, with an option to increase to 40 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clomipramine (Anafranil) after crossover from placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30268865

Group type: EXPERIMENTAL
Intervention: Transdermal androgen (AndroGel; Besins Healthcare, Brussels, Belgium)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28198147

Group type: EXPERIMENTAL
Intervention: %IHF
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Elevated liver enzymes, glycemic, lipid, and inflammatory biomarkers
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Triglycerides and chemerin
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: WC, alanine-aminotransferase, triglycerides/high-density lipoprotein cholesterol, and homeostasis model assessment of insulin resistance
Number of subjects: 275
Study: 26055051

Group type: EXPERIMENTAL
Intervention: Mindfulness program
Number of subjects: 125

Group type: COMPARATOR
Intervention: Physical activity program
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study: 24237728

Group type: EXPERIMENTAL
Intervention: Open‐eyed group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blindfolded group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 21266301

Group type: EXPERIMENTAL
Intervention: Fluoxetine plus voucher incentives (FV)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Fluoxetine without vouchers (F)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo plus voucher incentives (PV)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo without vouchers (P)
Number of subjects: 145
Study: 19076137

Group type: EXPERIMENTAL
Intervention: Continuous training programme (35‐59% of heart rate maximum reserve) for 8 weeks, 45‐60 min per session
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sedentary control group (21 age‐matched hypertensives, mean age 64 years, sd 8.53)
Number of subjects: 22
Study: 16952487

Group type: EXPERIMENTAL
Intervention: Microdose (100 microg) of diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic dose (10 mg) of diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microdose (100 microg) of midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic dose (7.5 mg) of midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microdose (100 microg) of ZK253
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic dose (50 mg) of ZK253
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microdose (100 microg) of warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic dose (5 mg) of warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microdose of erythromycin
Number of subjects: 0
Study: 15307692

Group type: COMPARATOR
Intervention: Sulfonylurea (Group A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Insulin (Group B)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of insulin and Chinese medicine (Group C)
Number of subjects: 84
Study: 11398518

Group type: EXPERIMENTAL
Intervention: Prednisone therapy (duration not exceeding 3 months)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prednisone therapy (duration 5 years on average)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 22
Study: 9014951

Group type: EXPERIMENTAL
Intervention: Involved vastus lateralis muscles (I-VL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Non-involved vastus lateralis muscles (N-VL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flexor hallucis longus muscles on the involved side (I-FHL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Vastus lateralis muscles of controls (C-VL)
Number of subjects: 8
Study: 7687807

Group type: EXPERIMENTAL
Intervention: GH (35 micrograms/h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study: 3706623

Group type: EXPERIMENTAL
Intervention: 10.0 mg/kg metrifonate (2 doses)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 7.5 mg/kg metrifonate (2 doses)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 10.0 mg/kg metrifonate (1 dose)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 30892799

Group type: EXPERIMENTAL
Intervention: Office hysteroscopy without a speculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional office hysteroscopy with a speculum
Number of subjects: 0
Study: 29528180

Group type: EXPERIMENTAL
Intervention: Caregiver-only adaptation of family-focused treatment (FFT) for 12-15 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard health education for 8-12 sessions
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Caregiver-only adaptation of family-focused treatment (FFT)
Number of subjects: 46